Reference : Ergotamine in the acute treatment of migraine: a review and European consensus.
Scientific journals : Article
Human health sciences : Neurology
Social & behavioral sciences, psychology : Neurosciences & behavior
Ergotamine in the acute treatment of migraine: a review and European consensus.
Tfelt-Hansen, P. [> > > >]
Saxena, P. R. [> > > >]
Dahlof, C. [> > > >]
Pascual, J. [> > > >]
Lainez, M. [> > > >]
Henry, P. [> >]
Diener, H. [> > > >]
Schoenen, Jean mailto [Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Neuro-anatomie >]
Ferrari, M. D. [> > > >]
Goadsby, P. J. [> > > >]
Brain: a Journal of Neurology
Oxford University Press
123 ( Pt 1)
Yes (verified by ORBi)
United Kingdom
[en] Analgesics, Non-Narcotic/pharmacokinetics/therapeutic use ; Ergotamine/pharmacokinetics/therapeutic use ; Europe ; Humans ; Migraine Disorders/classification/drug therapy
[en] Ergotamine has been used in clinical practice for the acute treatment of migraine for over 50 years, but there has been little agreement on its place in clinical practice. An expert group from Europe reviewed the pre-clinical and clinical data on ergotamine as it relates to the treatment of migraine. From this review, specific suggestions for the patient groups and appropriate use of ergotamine have been agreed. In essence, ergotamine, from a medical perspective, is the drug of choice in a limited number of migraine sufferers who have infrequent or long duration headaches and are likely to comply with dosing restrictions. For most migraine sufferers requiring a specific anti-migraine treatment, a triptan is generally a better option from both an efficacy and side-effect perspective.

There is no file associated with this reference.

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.